Malignancy in Systemic Lupus Erythematosus (SLE) patients

Rizna Abdul Cader, Amy Khoo Mei Yee, Azrul Yassin, Ismail Ahmad, Siti Nurfatin Haron

Research output: Contribution to journalArticle

Abstract

Background: Malignancies are among the leading causes of death in Systemic Lupus Erythematosus (SLE) patients with studies reporting a higher prevalence of malignancy in SLE patients compared to the general population. We wanted to determine the frequency of cancer in a cohort of SLE patients and identify its associated risk factors. Methods: Cross-sectional study involving SLE patients attending the nephrology outpatient clinic, Universiti Kebangsaan Malaysia Medical Centre between January and June 2014. Results: We recruited 228 patients (207 female, 21 male), aged 40.48 ± 12.86 years with mean SLE duration of 11.65 ± 6.46 years. Majority (87%) had lupus nephritis and were in remission with a median SLEDAI score 2 (0, 14). Majority (89%) were on corticosteroid with either a steroid sparing agent like mycophenolate mofetil (15.4%), azathioprine (36.8%) or ciclosporin (15.4%). One hundred and sixty (70.2%) patients were either receiving or had received intravenous cyclophosphamide with median dose of 5,173.6 ± 3,242.4 mg. Seven female patients were diagnosed with cancer during the course of their SLE with 56 (34-78) years being median age at malignancy and SLE duration of 4 (0-12) years. Majority (5/7) had lupus nephritis and all patients a median dose of prednisolone 10 (2.5, 10) mg with 10 (4-24) years of steroids. Two patients had a family history of cancer with majority developing cancer after the diagnosis of SLE. Two patients received intravenous cyclophosphamide prior to the development of cancer for their SLE compared to overall cohort of 160. Three patients had colorectal cancer, 2 had cervical cancer, 1 had breast cancer, and one patient had germ cell tumour and one thyroid cancer. All patients had their cancer successful treated with no signs of recurrence. Conclusion: We found a lower occurrence of cancer in our SLE patients as compared with the reported literature.

Original languageEnglish
Pages (from-to)3551-3555
Number of pages5
JournalAsian Pacific Journal of Cancer Prevention
Volume19
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Systemic Lupus Erythematosus
Neoplasms
Lupus Nephritis
Cyclophosphamide
Steroids
Mycophenolic Acid
Nephrology
Germ Cell and Embryonal Neoplasms
Malaysia
Azathioprine
Prednisolone
Ambulatory Care Facilities
Thyroid Neoplasms
Uterine Cervical Neoplasms
Cyclosporine
Cause of Death
Colorectal Neoplasms
Adrenal Cortex Hormones
Cross-Sectional Studies
Breast Neoplasms

Keywords

  • Cancer
  • Cyclophosphamide
  • Lupus nephritis
  • Malignancy
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Cite this

Malignancy in Systemic Lupus Erythematosus (SLE) patients. / Abdul Cader, Rizna; Yee, Amy Khoo Mei; Yassin, Azrul; Ahmad, Ismail; Haron, Siti Nurfatin.

In: Asian Pacific Journal of Cancer Prevention, Vol. 19, No. 12, 01.12.2018, p. 3551-3555.

Research output: Contribution to journalArticle

Abdul Cader, Rizna ; Yee, Amy Khoo Mei ; Yassin, Azrul ; Ahmad, Ismail ; Haron, Siti Nurfatin. / Malignancy in Systemic Lupus Erythematosus (SLE) patients. In: Asian Pacific Journal of Cancer Prevention. 2018 ; Vol. 19, No. 12. pp. 3551-3555.
@article{576804a64c41467daf982d374fe3eab1,
title = "Malignancy in Systemic Lupus Erythematosus (SLE) patients",
abstract = "Background: Malignancies are among the leading causes of death in Systemic Lupus Erythematosus (SLE) patients with studies reporting a higher prevalence of malignancy in SLE patients compared to the general population. We wanted to determine the frequency of cancer in a cohort of SLE patients and identify its associated risk factors. Methods: Cross-sectional study involving SLE patients attending the nephrology outpatient clinic, Universiti Kebangsaan Malaysia Medical Centre between January and June 2014. Results: We recruited 228 patients (207 female, 21 male), aged 40.48 ± 12.86 years with mean SLE duration of 11.65 ± 6.46 years. Majority (87{\%}) had lupus nephritis and were in remission with a median SLEDAI score 2 (0, 14). Majority (89{\%}) were on corticosteroid with either a steroid sparing agent like mycophenolate mofetil (15.4{\%}), azathioprine (36.8{\%}) or ciclosporin (15.4{\%}). One hundred and sixty (70.2{\%}) patients were either receiving or had received intravenous cyclophosphamide with median dose of 5,173.6 ± 3,242.4 mg. Seven female patients were diagnosed with cancer during the course of their SLE with 56 (34-78) years being median age at malignancy and SLE duration of 4 (0-12) years. Majority (5/7) had lupus nephritis and all patients a median dose of prednisolone 10 (2.5, 10) mg with 10 (4-24) years of steroids. Two patients had a family history of cancer with majority developing cancer after the diagnosis of SLE. Two patients received intravenous cyclophosphamide prior to the development of cancer for their SLE compared to overall cohort of 160. Three patients had colorectal cancer, 2 had cervical cancer, 1 had breast cancer, and one patient had germ cell tumour and one thyroid cancer. All patients had their cancer successful treated with no signs of recurrence. Conclusion: We found a lower occurrence of cancer in our SLE patients as compared with the reported literature.",
keywords = "Cancer, Cyclophosphamide, Lupus nephritis, Malignancy, Systemic lupus erythematosus",
author = "{Abdul Cader}, Rizna and Yee, {Amy Khoo Mei} and Azrul Yassin and Ismail Ahmad and Haron, {Siti Nurfatin}",
year = "2018",
month = "12",
day = "1",
doi = "10.31557/APJCP.2018.19.12.3551",
language = "English",
volume = "19",
pages = "3551--3555",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "12",

}

TY - JOUR

T1 - Malignancy in Systemic Lupus Erythematosus (SLE) patients

AU - Abdul Cader, Rizna

AU - Yee, Amy Khoo Mei

AU - Yassin, Azrul

AU - Ahmad, Ismail

AU - Haron, Siti Nurfatin

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Malignancies are among the leading causes of death in Systemic Lupus Erythematosus (SLE) patients with studies reporting a higher prevalence of malignancy in SLE patients compared to the general population. We wanted to determine the frequency of cancer in a cohort of SLE patients and identify its associated risk factors. Methods: Cross-sectional study involving SLE patients attending the nephrology outpatient clinic, Universiti Kebangsaan Malaysia Medical Centre between January and June 2014. Results: We recruited 228 patients (207 female, 21 male), aged 40.48 ± 12.86 years with mean SLE duration of 11.65 ± 6.46 years. Majority (87%) had lupus nephritis and were in remission with a median SLEDAI score 2 (0, 14). Majority (89%) were on corticosteroid with either a steroid sparing agent like mycophenolate mofetil (15.4%), azathioprine (36.8%) or ciclosporin (15.4%). One hundred and sixty (70.2%) patients were either receiving or had received intravenous cyclophosphamide with median dose of 5,173.6 ± 3,242.4 mg. Seven female patients were diagnosed with cancer during the course of their SLE with 56 (34-78) years being median age at malignancy and SLE duration of 4 (0-12) years. Majority (5/7) had lupus nephritis and all patients a median dose of prednisolone 10 (2.5, 10) mg with 10 (4-24) years of steroids. Two patients had a family history of cancer with majority developing cancer after the diagnosis of SLE. Two patients received intravenous cyclophosphamide prior to the development of cancer for their SLE compared to overall cohort of 160. Three patients had colorectal cancer, 2 had cervical cancer, 1 had breast cancer, and one patient had germ cell tumour and one thyroid cancer. All patients had their cancer successful treated with no signs of recurrence. Conclusion: We found a lower occurrence of cancer in our SLE patients as compared with the reported literature.

AB - Background: Malignancies are among the leading causes of death in Systemic Lupus Erythematosus (SLE) patients with studies reporting a higher prevalence of malignancy in SLE patients compared to the general population. We wanted to determine the frequency of cancer in a cohort of SLE patients and identify its associated risk factors. Methods: Cross-sectional study involving SLE patients attending the nephrology outpatient clinic, Universiti Kebangsaan Malaysia Medical Centre between January and June 2014. Results: We recruited 228 patients (207 female, 21 male), aged 40.48 ± 12.86 years with mean SLE duration of 11.65 ± 6.46 years. Majority (87%) had lupus nephritis and were in remission with a median SLEDAI score 2 (0, 14). Majority (89%) were on corticosteroid with either a steroid sparing agent like mycophenolate mofetil (15.4%), azathioprine (36.8%) or ciclosporin (15.4%). One hundred and sixty (70.2%) patients were either receiving or had received intravenous cyclophosphamide with median dose of 5,173.6 ± 3,242.4 mg. Seven female patients were diagnosed with cancer during the course of their SLE with 56 (34-78) years being median age at malignancy and SLE duration of 4 (0-12) years. Majority (5/7) had lupus nephritis and all patients a median dose of prednisolone 10 (2.5, 10) mg with 10 (4-24) years of steroids. Two patients had a family history of cancer with majority developing cancer after the diagnosis of SLE. Two patients received intravenous cyclophosphamide prior to the development of cancer for their SLE compared to overall cohort of 160. Three patients had colorectal cancer, 2 had cervical cancer, 1 had breast cancer, and one patient had germ cell tumour and one thyroid cancer. All patients had their cancer successful treated with no signs of recurrence. Conclusion: We found a lower occurrence of cancer in our SLE patients as compared with the reported literature.

KW - Cancer

KW - Cyclophosphamide

KW - Lupus nephritis

KW - Malignancy

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85058911870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058911870&partnerID=8YFLogxK

U2 - 10.31557/APJCP.2018.19.12.3551

DO - 10.31557/APJCP.2018.19.12.3551

M3 - Article

VL - 19

SP - 3551

EP - 3555

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 12

ER -